background: Human embryo biopsy is performed for preimplantation genetic diagnosis (PGD). The impact of 1-or 2-cell removal at cleavage-stage on future embryo development and implantation capacity is highly debated.
Introduction
Preimplantation genetic diagnosis (PGD), as well as preimplantation genetic aneuploidy screening (PGS), implies the removal of either polar bodies, blastomeres or trophectoderm (TE) cells from oocytes, cleavage-stage embryos and blastocysts, respectively (De Vos and Van Steirteghem, 2001) . The ESHRE PGD consortium data collection (Harper et al., 2008) illustrates that for clinical PGD, cleavage-stage embryo biopsy is performed far more commonly than polar body removal and TE biopsy. Despite reporting on the zona opening procedure used (mechanical, chemical or laser technology) , no details on whether one or two blastomeres are removed from the embryos are available.
Human embryo biopsy for PGD should be envisaged as a balance between cell retrieval in order to allow a safe and correct diagnosis of the embryo on the one hand, and safeguarding the implantation potential of the biopsied embryo on the other. Hardy et al. (1990) concluded that removal of one or two cells at the 8-cell stage, although reducing the cellular mass, does not adversely affect its further in vitro development, nor does it interfere with the inner cell mass(ICM)/TE ratio (allocation), suggesting that this approach could be used for PGD. In 1998, following a misdiagnosis using single cell biopsy and PCR (Sermon et al., 1998) , and taking into consideration the required efficiency, accuracy and reliability of a diagnosis, we have always advised to analyse two cells from a 7-cell stage embryo, in order to meet the limitations of FISH and PCR techniques. Van de Velde et al. (2000) reported an acceptable ongoing pregnancy rate (29.1%) and implantation rate (18.6%) per transfer when two cells were removed from the embryo. However, a limitation of that study, as indicated by the authors, was its non-randomized nature.
The reported pregnancy rates could not be readily compared between groups because the 2-cell group contained more rapidly developing and therefore 'better quality' embryos. Technical improvements at the diagnostic level (multiplex PCR, multicolor FISH), however, have allowed similar diagnostic accuracy to be obtained on one blastomere compared with two blastomeres for certain indications or tests (Lewis et al., 2001; Wells, 2004) . Indeed, in cases where sufficient diagnostic safety measures are in place to ensure a correct diagnosis on one cell, one could minimally compromise future embryo development by removing only one blastomere (Cohen et al., 2007) . Goossens et al. (2008) clearly showed a significant influence of the embryo biopsy procedure on blastocyst formation rate and quality. Removing one blastomere was less invasive than 2-cell removal, thus resulting in more top quality, good quality and early blastocysts on Day 5. Despite this embryological finding, the randomized control trial did not demonstrate a significant difference in clinical outcome between the two biopsy approaches. Delivery rates with live birth per started cycle were not different: 20.2% for 1-cell biopsy and 17.2% for 2-cell biopsy (P-value 0.358). However, critical appraisal of the data made the authors conclude to recommend 1-cell biopsy whenever possible and allowing for an accurate diagnosis.
The study by Goossens et al. (2008) reflects true clinical observations, with biopsy performed on a cohort of unselected embryos. Blastomere removal is performed at the embryonic level, whereas clinical outcome is expressed at the level of started cycle per patient. Indeed, whenever more than one genetically transferable embryo (GTE) is available and whenever the best embryo can be chosen for transfer, the true impact of the biopsy procedure on implantation capacity might be blurred.
In order to evaluate the true impact of embryo biopsy at the cleavage stage on future blastocyst development and implantation, we analysed a cohort of single blastocyst transfers at Day 5 of embryo development, with the transferred embryo strictly stemming from an 8-cell embryo at Day 3, and from which either one blastomere or two blastomeres were removed for genetic diagnosis. A control cohort of unselected ICSI patients, treated in the same period and in the same way except without the biopsy procedure, was included in the analysis to provide insight into the way embryo biopsy (either one or two cells) relates to no invasion performed on the embryo.
Materials and Methods

Study design
Between February 2004 and December 2007, we collected all Day 5 single blastocyst transfers, where the transferred blastocyst resulted from an 8-cell embryo on Day 3. Three groups were distinguished: group I, 1-cell biopsy (n ¼ 182); group II, 2-cell biopsy (n ¼ 259) and group III, no biopsy of the 8-cell embryo on Day 3 (n ¼ 702). Group II and III were exclusively ICSI patients. Group I included three IVF cycles (all in combination with FISH for PGD). In all groups, patients that presented for a second or third time were excluded from the analysis. Thus, the number of cycles/transfers equals the number of patients. All three groups were similar in terms of chronological distribution over the 4 year study period (Fig. 1) .
This prospective cohort study covers 4 years of PGD and ICSI experience at a University Hospital. The period is unique in that 1-cell and 2-cell biopsy were performed in parallel. One-cell biopsy was applied for these indications where sufficient diagnostic safety measures were in place to ensure a correct diagnosis. Two-cell biopsy was used for the other indications where this was not the case. PGS was initially done on two blastomeres, but was switched to the 1-cell biopsy strategy from October 2005 onwards, based on data published by Michiels et al. (2006) and Goossens et al. (2008) . Due to overlap in time, a minority of cycles reported here are also featured in the Goossens et al. (2008) study: 38 cycles in group I (i.e. 21% of all cycles in group I) and 49 cycles in group II (i.e. 19% of all cycles in group II). The ICSI reference population included all patients that received a Day 5 single embryo transfer (SET) (resulting from an 8-cell embryo on Day 3) in an unselected manner. Figure 1 Chronolgical distribution of oocyte retrieval from patients recruited into the three study groups.
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Diagnostic tests
For the two biopsy groups, the distribution by diagnostic test (PCR, FISH, PGS) and indication is reported in Table I . Significantly more PGS cycles were represented in group I, the majority being a significant number of younger patients that were enrolled in a study analysing aneuploidy in women below 36 years of age . Group II contained significantly more strict sense PGD by means of PCR (mainly autosomal dominant indications) or FISH (mainly reciprocal translocations). In order to correct for this different distribution in group I and group II, the number of GTEs obtained in the two groups (found to be significant in the univariate analysis) was included as an adjusting (independent) variable in the multivariable (logistic regression) analysis with live birth as the outcome (dependent) variable.
Outcome measures
Baseline characteristics of the three groups included maternal age and rank of trial. In order to illustrate the male factor infertility in group III compared with the other two groups, the proportion of cycles with an ejaculate semen sample (as opposed to surgically retrieved sperm cells) is given, as well as the initial semen concentration of the ejaculate samples used in the three groups. Cycle characteristics included number of retrieved cumulus-oocyte complexes, number of inseminated/injected oocytes, number of fertilized oocytes and number of 8-cell embryos on Day 3. For the two biopsy groups, the number of biopsied embryos and the number of GTEs are given as well. Embryo development on Day 3 is illustrated for the three groups. Embryo development on Day 5 was taken as a secondary outcome measure, whereas live birth delivery was the sole primary end-point of the study.
Ovarian stimulation
Patients underwent ovarian stimulation either by a long GnRH agonist protocol using buserelin (Suprefact; Hoechst, Frankfurt, Germany) combined with HMGs (Menopur; Ferring Pharmaceuticals A/S). Otherwise, a combination of GnRH antagonist (Orgalutran; NV Organon, Oss, The Netherlands) and recombinant gonadotrophins (rFSH, Puregon; NV Organon) was used (Kolibianakis et al., 2004) . Final oocyte maturation was achieved by 10 000 IU of HCG (Pregnyl; NV Organon) as soon as three follicles of 17 mm diameter were present on ultrasound.
Fertilization, embryo development and embryo biopsy ICSI was performed as previously described (Van Landuyt et al., 2005) . Sixteen to eighteen hours post-injection, fertilization was assessed and further development of the embryos was evaluated on a daily basis. For embryo evaluation on Day 3, the developmental stage was registered and the embryos were further classified according to the percentage of fragmentation. Signs of compaction in the embryos were scored as compacting (C1, cell borders are still visible) or compact (C2, a dense morula is formed).
Embryos with ,50% of fragmentation and with at least six blastomeres were biopsied in the morning of Day 3 after injection as previously described (Joris et al., 2003; Goossens et al., 2008) . Five-cell embryos were only included in cases of 1-cell biopsy. G-PGD (Vitrolife, Kungsbacka, Sweden) was used as decompaction medium. After biopsy, the embryos were transferred to the sequential medium for blastocyst culture (BlastAssist w System, Medicult, De Pinte, Belgium or GIII series, Vitrolife, Kungsbacka, Sweden). In group III, medium was also changed on Day 3 of culture.
Day 5 blastocyst evaluation was done as described by Gardner et al. (2000) . Blastocysts 1 and 2 were considered as early blastocysts. Good quality blastocysts included all other expanded stages (3-6, at least type BA or BB) and excellent quality blastocysts included stages 3 -6, types AA or AB. The first index refers to the quality of the ICM and the second index refers to the quality of the TE. Early (artificial) hatching of the blastocyst through the biopsy opening in the zona pellucida was recorded as stage 7. Typing of the ICM and TE of these blastocysts was done similarly as mentioned above.
Clinical outcome
Along the criteria set out by the International Committee Monitoring Assisted Reproductive Technologies (ICMART) (Zegers-Hochschild et al., 2006) , the following events were assessed for each patient: preclinical abortion, miscarriage, clinical (including extra-uterine) pregnancy, elective termination, stillbirth and live birth (singleton or multiple) delivery. A preclinical pregnancy was defined as two consecutive positive rising (.15 IU/ml) serum hCG levels, measured 14 days after oocyte aspiration and with an interval of 3 days. A preclinical abortion was therefore defined as an abortion before clinical ultrasound evidence of pregnancy. A miscarriage was defined as a clinical pregnancy loss before 20 weeks of gestation. defined as a birth in which a fetus was delivered with signs of life after complete expulsion or extraction from its mother, beyond 20 completed weeks of gestational age. Live births were counted as birth events, i.e. a twin or multiple birth was counted as one birth event (Zegers-Hochschild et al., 2006) . Follow-up data on pregnancies and deliveries were prospectively collected via questionnaires given to the patients at the day of transfer (Bonduelle et al., 2002) .
Statistical analyses
Categorical variables are presented as number of cases or percentages including nominator and denominator values. Continuous variables are summarized with the use of means + SD (baseline characteristics and secondary outcome measures) for each group of interest. The patient groups were compared by using x 2 tests for categorical variables, and independent Student t test (2 groups) or analysis of variance (ANOVA) techniques (3 groups) for continuous variables. After an ANOVA had resulted in a significant F test with a P-value of ,0.05, pairwise comparisons using Tukey's honest significant difference procedure were made.
To adjust for differences in baseline characteristics we used multivariable (logistic regression) analyses with live birth as the outcome (dependent) variable, and baseline characteristics found to be significant in the univariate analyses as the adjusting (independent) variables.
Analyses were performed in the statistical package SPSS, version 16.0 (2008 SPSS Inc, Chicago, IL, USA).
Results
Baseline characteristics and cycle characteristics of group I, group II and group III In this study 1143 single Day 5 transfers were performed in our centre between February 2004 and December 2007 with blastocysts resulting from 8-cell embryos on Day 3. In group I (n ¼ 182), one blastomere was removed on Day 3 for genetic testing. In group II (n ¼ 259), two cells were biopsied from the embryo that was finally transferred on Day 5. Group III (n ¼ 702) represents a non-biopsy control group, being a cohort of unselected ICSI patients treated during the same period in the same way as the two other groups, except for the biopsy procedure.
Baseline characteristics and cycle characteristics of the three groups are presented in Table II . The two biopsy groups did not differ for any of these parameters, except for the number of GTEs obtained (being related to the genetic indications included in the two groups as illustrated in Table I ).
The ICSI patients (group III) were on average 3 years younger than the PGD/PGS patients; 30.0 years (SD 3.7, range 19 -40) (P , 0.001 versus group I and P , 0.001 versus group II, post-hoc comparisons by Tukey honest significant difference test). Part of this age difference was accounted for by the presence of patients older than 40 in the two biopsy groups (respectively 19 in group I and 12 in group II, mainly PGS cycles for advanced maternal age). These patients were not represented in the control group because they received either Day 3 transfer or had more than one embryo transferred in our programme. The rank of trial in group III, 1.4 (SD 0.9), was significantly lower compared with group I (P ¼ 0.010) and group II (P , 0.001).
In order to illustrate the paternal infertility factor in group III, the proportion of cycles with ejaculate sperm was reported (Table I) . Group III contained significantly fewer cycles with ejaculate sperm compared with group I (91.2 versus 96.2%, P ¼ 0.026, post-hoc comparison by Tukey honest significant difference test). The initial concentration (10 6 /ml) of the ejaculate samples were significantly lower in group III compared with group I (P , 0.001) and group II (P , 0.001).
Cycle characteristics included number of retrieved cumulus -oocyte complexes (12), number of inseminated/injected oocytes (10) number of fertilized oocytes (7) and number of 8-cell embryos on Day 3 (3). The two biopsy groups were comparable for all these characteristics. In these two groups, on average 5.5 (SD 3.6) (group I) and 4.9 (SD 3.1) (group II) embryos were biopsied per cycle (P ¼ 0.11 by Student t-test). On average 2.5 (SD 2.2; group I) and 1.9 (SD 1.6; group II) GTEs were obtained, and was significantly higher for group I compared with group II (P ¼ 0.002 by Student t-test).
Embryo development Day 3
In the three groups, embryo development Day 3 was expressed per number of fertilized oocytes obtained. The data are presented in Table III . None of the groups differed in the distribution of the embryos over the three fragmentation categories (P ¼ 0.054 for one-way ANOVA When expressed per number of fertilized oocytes, similar percentages of embryos were biopsied in the two groups: 73.2% (SD 21.3) in group I and 71.2% (SD 23.1) in group II (P ¼ 0.36). Despite inclusion of 5-cell embryos in group I and not in group II, the mean developmental stage of the biopsied embryos did not differ between the two groups (7.66, SD 0.70 in group I and 7.75, SD 0.61 in group II, P ¼ 0.15). The Day 3 developmental stage of the GTEs was also similar in the two groups (7.86, SD 0.45 in group I and 7.91, SD 0.47 in group II, P ¼ 0.26).
Embryo development Day 5
Day 5 embryo development was expressed per number of 8-cell embryos on Day 3 (Table IV) . Blastocyst formation was significantly better in group III compared with group II (P , 0.001, pairwise comparison by Tukey honest significant difference test). Blastocyst formation in group I did not differ significantly from group III (P ¼ 0.53). When comparing the two biopsy groups, no statistical significance was reached (P ¼ 0.23).
The cohort of embryos actually transferred in group I consisted of 22.5% early blastocysts, 7.1% good quality blastocysts and 54.9% excellent quality blastocysts. In group II, these figures were 19.7, 18.5 and 40.9% respectively. In group III, up to 75.5% of the transferred blastocysts were of excellent quality, 7.1% were of good quality and 11.4% were early blastocysts. However, because no genetic restriction in embryo choice for transfer exists in group III, the latter figures cannot be readily compared with the two biopsy groups.
Clinical outcome
The clinical outcome of this prospective cohort study is summarized in Table V . The percentage of positive hCG per SET was 46.7% in group I, comparable to group III (48.6%, P ¼ 0.65), however, significantly higher compared with group II (36.3%, P ¼ 0.028). Similarly, the live birth rate per transfer was 37.4% in group I, comparable to group III (35.0%, P ¼ 0.59), however, significantly higher compared with group II (22.4%, P , 0.001). Table VI ratio was adjusted for all factors found to be significant in the univariate analyses of Tables II and III. The adjusted odds ratio (0.477 CI 0.306-0.743) confirmed the significant difference between group I and group II (1-cell and 2-cell biopsy, P ¼ 0.001). The live birth delivery rate in group I (1-cell biopsy) did not differ from that in group III (no embryo biopsy) (P ¼ 0.19).
As illustrated in Table VII , three types of single blastocyst transfer were distinguished for the two biopsy groups. There were transfers where only one GTE was available. This occurred more frequently in group II (55.0% of all transfer cycles) compared with group I (44.5% of all transfer cycles), related to the genetic indications included in group II (see Table I : autosomal dominant indications, HLA typing, and reciprocal translocations were more highly represented in group II; aneuploidy screenings below 36 years of age more abundant in group I). The transfer of a single available genetically transferable blastocyst resulted in a live birth rate of 25.9% in group I compared with 18.2% in group II. Having more than one GTE resulted in a live birth rate of 46.5% in group I compared with 27.6% in group II. In these cases with more than one GTE, Day 5 development postbiopsy determines whether elective transfer (at least one healthy or chromosomally normal embryo frozen additional to the one transferred) is possible or not (in the latter case non-elective transfer). Elective SET was possible in 59.4% of these cases in group I and in only 41.4% of these cases in group II. Live birth rates for elective SET were 55.0 and 35.4%, respectively, for group I and group II. Live birth rates for non-elective transfers were respectively 34. 2 test for testing the difference between the three groups P ¼ 0.003. Pairwise comparisons: group I versus group II, P ¼ 0.028; group I versus group III, P ¼ 0.65; group II versus group III, P , 0.001. f Overall x 2 test for testing the difference between the three groups P , 0.001. Pairwise comparisons: group I versus group II, P , 0.001; group I versus group III, P ¼ 0.56; group II versus group III, P , 0.001.
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Discussion
The objective of this study was to evaluate the true impact of 1-or 2-cell removal in a homogeneous Day 3 8-cell embryo population. ICSI patients where no biopsy was performed on the embryo served as a reference population. SETs on Day 5 were selected for the analysis. Taking live birth delivery rate per transfer cycle as the end-point, the present study showed that 1-cell biopsy gave similar results (37.4%) compared with the ICSI population without embryo biopsy (35.0%), even when corrected for maternal age and paternal factor infertility. Two-cell biopsy, on the other hand, was shown to be more detrimental, resulting in a 40% reduction in live birth rate (22.4%). For a long period, 2-cell biopsy has been the golden standard for PGD and PGS at our centre, in order to ensure a safe and correct diagnosis. However, technical diagnostic improvements (multiplex PCR, multicolor FISH) allowed a gradual transition towards 1-cell biopsy. Data from Michiels et al. (2006) and the outcome of a controlled trial also provide evidence to consider 1-cell biopsy a valid alternative for 2-cell biopsy. Having changed our embryo biopsy strategy from 2-cell to 1-cell removal wherever possible (since October 2005) gave a unique dataset (2004 -2007) that was analysed prospectively for embryo development post-biopsy and delivery live birth after Day 5 SET. The two biopsy groups were comparable for all baseline patient and cycle characteristics. Similar embryo quality Day 3 (mean developmental stage and fragmentation type) was observed and similar numbers of embryos of equal mean developmental stage were biopsied.
It must be stated, however, that the indications for embryo biopsy were not similar in the two groups: having more PGS cycles in group I and more strict sense PGD, by means of PCR or FISH, in group II. This kind of bias was reflected in the number of GTEs that were available in the two groups, being significantly lower in group II (1.9, SD 1.6) than in group I (2.5, SD2.2). Multivariable logistic regression analysis allowed to correct for this parameter, so to exclude any possible genetic bias present.
The present study reported an average cell number on Day 3 for the two biopsy groups (6.62) and the younger ICSI population (6.83). These figures are in agreement with the average Day 3 cell number (6.7) as reported by Cohen et al. (2007) . On Day 3, it is wellknown that most patients present a diversity of embryos at different cell stages. In order to focus on the impact of embryo biopsy on 8-cell embryos, embryo development Day 5 was expressed per number of 8-cell embryos on Day 3. Thereby, the difference between the two biopsy groups and the ICSI group (presenting more 8-cell embryos per fertilized oocyte) was alleviated, allowing a direct comparison of Day 5 developmental competence of biopsied embryos (either one or two cells) and unmanipulated embryos. Although the cycles reported here are not entirely independent of those reported in the Goossens study, the overlap is small and Table II ). e One cycle with positive hCG was lost for follow up after hCG measurement.
therefore comparison of the results is justified. The present overall blastocyst formation rates in the two biopsy groups (63.6% in group I and 57.6% in group II) correspond well with figures reported by Goossens et al. (2008) : 63.5% for 8-cell embryos in the 1-cell biopsy group and 56.0% for 8-cell embryos in the 2-cell biopsy group (extracted from Fig. 2 of Goossens et al., 2008) . The confirmational finding that fewer blastocysts resulted after 2-cell biopsy than after 1-cell biopsy needs to be underlined, despite the fact that no statistical significance was reached here. An interesting, sofar unknown, finding is the present comparison with unmanipulated embryos. Two-cell biopsy resulted in a significantly lower blastocyst formation rate compared with when no invasive procedure was perfromed on Day 3. The fact that 1-cell biopsy, in contrast, performed equally well as no biopsy points to a disproportionate decline in embryo developmental competence. The fundamental question whether simple mass reduction and/or a disturbed ICM/TE allocation forms the basis of this finding remains open. The true effect of human cleavage-stage biopsy on in vivo implantation potential is poorly documented. Current understanding is based on experiments with spare human embryos measuring in vitro end-points (Hardy et al., 1990; Tarin et al., 1992) . Additional evidence for its possible detrimental effect has been sought in embryo cryopreservation data, assuming that cell loss from biopsy can be compared with cell loss after thaw of frozen cleaved embryos (Tang et al., 2006; Cohen et al., 2007) . A disproportionate reduction in implantation potential according to the cell number lost has been described. The loss of 25% or more of blastomeres seems relatively more severe compared with smaller proportional losses (76 -99% blastomere survival), resulting in an implantation potential decrease as high as 54 -59% (Tang et al., 2006; Cohen et al., 2007) . These indirect estimates from cryopreservation analogy (including different cleavage stages) correspond well with the present evidence, i.e. a 40% reduction in live birth implantation was observed between group I and group II (8-cell stage only). Whether the difference between 54 -59% and 40% falls within an acceptable range of variation, is due to the difference in cell stage between studies or whether it represents a true additional effect of the cryopreservation protocol/procedure remains unanswered.
Regardless the fact that more GTEs were available in group I than in group II, the mean developmental stage on Day 3 of the GTEs was identical in the two biopsy groups. Whenever more than one GTE is available, the transfer type-elective or non-elective-entirely depends on the embryology post-biopsy. The finding that more transfer cycles (with .1 GTE) were elective in group I (59.4%) compared with group II (41.4%) indicates a better post-biopsy development after 1-cell removal. GTE availability (higher in group I due to genetic bias) together with post-biopsy Day 5 embryo development (better after 1-cell removal), resulted in one third of the transfer cycles being elective in group I compared with only one fifth in group II. After correction for the genetic bias against group II, the true Day 5 post-biopsy developmental advantage for group I was reflected in a significantly better clinical outcome.
The present study indisputably shows that 8-cell embryos having lost two blastomeres by embryo biopsy have a 40% lower implantation potential compared with 8-cell embryos having lost only one blastomere. Interestingly enough, the live birth rate after 1-cell biopsy was comparable to that of unmanipulated 8-cell embryos in cases of SET Day 5. This latter finding argues against an additional detrimental effect of the zona-breaching method or suboptimal environmental conditions during micromanipulation on the implantation potential of the embryos .
In part responsible for the significantly lower live birth rate per transfer cycle in group II is the high loss due to preclinical abortion and miscarriage (respectively 16 and 15 of the 94 positive hCGs are lost; i.e. 17.0 and 16.0%). This loss is higher compared with group I (respectively 9/85, i.e. 10.6% and 6/85, i.e. 7.1%) and group III (respectively 43/341, i.e. 12.6% and 37/341, i.e. 10.9%) which showed comparable losses. We have no clear explanation for this observation. Conversely, Goossens et al. (2008) reported an inverse rate of clinical abortions (miscarriages): 8/97, i.e. 8.3% in the 1-cell group and 2/82, i.e. 2.4% in the 2-cell group. Preclinical abortions were comparable in their two study groups (albeit higher than in the present study, however, not readily comparable because of the selected cohort here, i.e. single Day 5 transfers strictly stemming from an 8-cell stage at Day 3). Probably, the low numbers (less than 100 positive hCGs) make it difficult to distinguish between a random and a true observation. From the present cohort, we were unable to conclude a possible link with poorer embryo quality at transfer. One biochemical pregnancy in group I involved a poor quality early blastocyst, whereas all other losses involved early, good or top quality blastocysts. In group II, six losses involved poor quality embryos: two poor quality morulas (one biochemical and one miscarriage), one poor quality early blastocyst (miscarriage) and three advanced poor quality blastocysts (biochemical) were transferred.
The data presented here clearly indicates that two cell biopsy significantly impacts clinical outcome. Our previous report providing no arguments in favour of PGS for advanced maternal age cases (Staessen et al., 2004) was criticised by others arguing that PGS might have been beneficial if only one cell had been removed (Cohen et al., 2007) . In respect to the present findings, this criticism seems justified. However, a final answer to this open question can only be provided by a new similar RCT using 1-cell biopsy instead of 2-cell biopsy. More recently we have reported on the potential benefit of PGS in women under the age of 36 following SET . Despite having adopted the 1-cell biopsy approach in that study, we observed no improvement in delivery rate.
Having documented the effect of 2-cell removal on a homogeneous population of 8-cell embryos, one can imagine that a similar cell loss would even be more detrimental for 7-and 6-cell embryos that are indeed included in clinical embryo biopsy practice. Whereas so far no consensus exists on the number of blastomeres that can be safely removed during cleavage stage biopsy (Thornhill et al., 2005) , the present data should facilitate the making of informed choices between the biopsy of one cell (given sufficient diagnostic safe guards for an accurate and reliable diagnosis) or two cells (at the expense of implantation potential as reported here).
